Atria Wealth Solutions Inc. Sells 7,742 Shares of iShares Biotechnology ETF $IBB

Atria Wealth Solutions Inc. lowered its position in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 58.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,502 shares of the financial services provider’s stock after selling 7,742 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in iShares Biotechnology ETF were worth $703,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of IBB. Citigroup Inc. boosted its position in iShares Biotechnology ETF by 88.5% during the first quarter. Citigroup Inc. now owns 3,208,144 shares of the financial services provider’s stock valued at $410,322,000 after acquiring an additional 1,505,976 shares during the last quarter. Millennium Management LLC boosted its position in iShares Biotechnology ETF by 140.8% during the first quarter. Millennium Management LLC now owns 41,676 shares of the financial services provider’s stock valued at $5,330,000 after acquiring an additional 143,893 shares during the last quarter. Jones Financial Companies Lllp boosted its position in iShares Biotechnology ETF by 763.3% during the first quarter. Jones Financial Companies Lllp now owns 151,265 shares of the financial services provider’s stock valued at $19,347,000 after acquiring an additional 133,744 shares during the last quarter. Madrona Financial Services LLC boosted its position in iShares Biotechnology ETF by 153.0% during the first quarter. Madrona Financial Services LLC now owns 81,150 shares of the financial services provider’s stock valued at $10,379,000 after acquiring an additional 49,075 shares during the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. boosted its position in iShares Biotechnology ETF by 35.0% during the second quarter. Generali Investments CEE investicni spolecnost a.s. now owns 116,115 shares of the financial services provider’s stock valued at $14,690,000 after acquiring an additional 30,115 shares during the last quarter. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Trading Up 0.5%

Shares of NASDAQ IBB opened at $154.19 on Friday. The firm’s 50-day moving average price is $142.93 and its 200-day moving average price is $131.44. iShares Biotechnology ETF has a 1-year low of $107.43 and a 1-year high of $156.36.

iShares Biotechnology ETF Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 19th. Stockholders of record on Tuesday, September 16th were issued a dividend of $0.0828 per share. The ex-dividend date was Tuesday, September 16th. This represents a $0.33 annualized dividend and a dividend yield of 0.2%.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.